Immunovant
Sheetal is a physician with more than 20 years of experience in academia and the biopharmaceutical industry. She has held key roles in all phases of clinical development, medical affairs, and data generation. She has led cross-functional teams for filing multiple BLA, NDA, and device submissions, bringing multiple products to market. Her skillsets expanse from Phase I-IV, registrations trials, prelaunch, launch, and LCM in various therapeutic areas globally. Sheetal has worked across large and small biopharmaceutical companies, including Baxter, Abbott, Shire, Takeda, Bayer, Exact Sciences, Relmada, and Lundbeck. She also held positions at Rush University Medical Center and the University of Illinois and other Chicago Hospitals prior to making her transition to industry.
This person is not in any offices
Immunovant
6 followers
Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Immunovant is developing IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies.